ITMN itself does not appear to be especially confident of FDA approval on the first review cycle despite the favorable vote by the advisory panel (#msg-49605220). On the other hand, the odds of first-cycle approval would seem to be better than for BMY’s Belatacept (#msg-49686117) for the simple reason that there is no approved therapy for IPF.
Market Data 
Markets 
AI
